The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
Open accessAbstract
The human gut microbiome has been linked to numerous digestive disorders, but its metabolic products have been much less well characterized, in part due to the expense of untargeted metabolomics and lack of ability to process the data. In this review, we focused on the rapidly expanding information about the bile acid repertoire produced by the gut microbiome, including the impacts of bile acids on a wide range of host physiological processes and diseases, and discussed the role of short-chain fatty acids and other important gut microbiome-derived metabolites. Of particular note is the action of gut microbiome-derived metabolites throughout the body, which impact processes ranging from obesity to aging to disorders traditionally thought of as diseases of the nervous system, but that are now recognized as being strongly influenced by the gut microbiome and the metabolites it produces. We also highlighted the emerging role for modifying the gut microbiome to improve health or to treat disease, including the "engineered native bacteria'' approach that takes bacterial strains from a patient, modifies them to alter metabolism, and reintroduces them. Taken together, study of the metabolites derived from the gut microbiome provided insights into a wide range of physiological and pathophysiological processes, and has substantial potential for new approaches to diagnostics and therapeutics of disease of, or involving, the gastrointestinal tract.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bile acids have the potential to modulate the gut-brain axis by maintaining intestinal homeostasis, as TGR5 and FXR signaling are pivotal regulators of intestinal immune response and barrier function.
“Moreover, BAs have the potential to modulate the gut–brain axis by maintaining intestinal homeostasis, as TGR5 and FXR signaling are pivotal regulators of intestinal immune response and barrier function.365,376”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [365]
UDCA and TUDCA exert anti-inflammatory effects by activating the nuclear receptor FXR and membrane receptor TGR5, both found in microglia and neurons.
“They exert anti-inflammatory effects by activating the nuclear receptor Farnesoid X receptor (FXR) and membrane receptor Takeda G-protein-coupled receptor 5 (TGR5), both of which are found in microglia and neurons.365,366”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [365]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 219 · Cited by 177
- Authors
- Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R.
- Affiliations
- University of California San Diego (US)
- Veterans Health Administration (US)
- Corresponding author
- Dorrestein, Pieter C.
- Zarrinpar, Amir
- Knight, Rob
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 164
- Issue
- 7
- Pages
- 1069-1085
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC10205675
- OpenAlex
- W4321794491
- Cited by
- 177
- References
- 219
- Citations by year
- 2026: 66 · 2025: 66 · 2024: 35 · 2023: 10
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-01-01)
- Open access
- hybrid
- doi.org
- Locations
- Gastroenterology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (DP1AT010885, T32 DK007202, U19AG063744)
- U.S. Department of Veterans Affairs (R01 EB030134, R01 HL148801, U01 CA265719)
- Veterans Health Administration Rehabilitation Research & Development Service (I01 BX005707)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, bile acids, gut microbiota metabolites, short-chain fatty acids, gut health, gastrointestinal diseases, obesity, aging, neurological disorders, microbiome engineering, untargeted metabolomics
- MeSH terms
- Gastrointestinal Microbiome, Microorganisms, Genetically-Modified, Bile Acids and Salts, Fatty Acids, Volatile, Humans, Metabolome, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review